CORRELATION BETWEEN MAGNESIUM SERUM LEVELS AND PEAK EXPIRATORY FLOW IN CHRONIC ASTHMA PATIENTS by Yonarko, Grendi Faneri et al.
16
O R I G I N A L  A R T I C L E
CORRELATION BETWEEN MAGNESIUM SERUM LEVELS AND PEAK 
EXPIRATORY FLOW IN CHRONIC ASTHMA PATIENTS
 
1 2 3*Grendi Faneri Yonarko , Suhardi DA. , Barmawi Hisyam  
1. Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta
2. Division of Nephrology, Department of Internal Medicine, Dr. Sardjito General Hospital, Yogyakarta
3. Division of Pulmonology, Department of Internal Medicine, Dr. Sardjito General Hospital, Yogyakarta
*Corresponding Author: bmwhsparu2007@yahoo.com
ABSTRACT
Background: Magnesium Serum in some 
previous studies had been related to asthma events 
and severity levels. Correlation between magnesium 
serum levels and severity of asthma was 
controversies. It might be influenced by race, genetic 
pattern, diet and demography factor. 
Objective: The objective of this study was to 
know relationship between magnesium serum levels 
and predictive PEF (Peak Expiratory Flow) in 
chronic asthma patients in Yogyakarta.
Method: This was a cross-sectional study; 
subjects were asthma patients who visited 
Pulmonology Outpatient Department in Dr. Sardjito 
General Hospital Yogyakarta, from September 2004 
- March 2005. We performed clinical evaluation, 
magnesium serum levels (normal 0.65 mmol/L-1.04 
mmol/L), predictive PEF and medications. 
Correlation between magnesium serum levels and 
PEF were analyzed by Pearson correlation test. This 
study used analysis of variance (anova) to analyze 
mean difference among more than 2 groups and 
multiple regressions to know the variables which 
influenced serum magnesium levels.
Result: There were 62 asthma patients in 
this study. There was no hypomagnesaemia. The 
mean of magnesium was 0.89 ± 0.08 mmol/L. Results 
showed that serum magnesium levels and predictive 
PEF had weak correlation (r= 0.281; p=0.027). 
There was no significant correlation between 
admission rate to Emergency Room due to asthma by 
magnesium levels (r=0.029 p= 0.8). 
Conclusion: Results showed weak 
relationship serum magnesium levels and PEF in 
chronic asthma patients.
Keywords: bronchial asthma; serum magnesium 
levels, Peak Expiratory Flow rate 
INTRODUCTION
Asthma is a serious problem. The 
prevalence of asthma increased in the developing 
1country during the last 20 years . The increasing 
number of asthma patients registered in Indonesia is 
2approximately 5-7% . Magnesium might be a risk 
factor for severity of asthma. Magnesium is closely 
involved in numerous important biochemical 
reactions in the body, particularly those processes 
that entail the formation and utilization of ATP. As a 
cofactor of over 300 intracellular enzyme reactions 
utilizing high-energy phosphate bonds, magnesium 
3,4has been implicated in smooth muscle contraction . 
In fact, magnesium is a chemical element with 
modulator effects on the contractile state of smooth 
muscle cells in various tissues: hypomagnesaemia 
leads to contraction and hypermagnesaemia leads to 
relaxation. Magnesium has been shown to relax 
bronchial smooth muscle in vitro and to 
4,5,6bronchodilate asthmatic airways in vivo . 
Potential mechanisms for the direct relaxing effects 
of magnesium on bronchial smooth muscle was 
including calcium channel blocking properties, 
inhibition of cholinergic neuromuscular 
transmission with decreased sensibility to the 
depolarizing action of acetylcholine, stabilization of 
mast cells, and reduce respiratory burst activity of 
5neutrophil .
In accordance with this hypothesis, a study 
involving 2,633 subjects in England, demonstrated 
that dietary magnesium intake is independently 
related to lung function and to the occurrence of 
7airway hyperreactivity, and wheezing .Asthma 
patients with hypomagnesaemia had a correlation 
with severi ty of  asthma compare with 
8normomagnesaemia population .Study with 33 
subjects in Thailand found serum magnesium in 
severe asthma low than serum magnesium in normal 
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9population . Some studies and meta-analysis 
reported that magnesium intravenous effective to 
treat intermediate and severe acute exacerbation of 
10,11,12,13asthma .
Correlation between serum magnesium and 
asthma is controversy. The concentration of serum 
magnesium in asthma population in Yogyakarta is 
unknown. The prevalence of hypomagnesaemia and 
evidence of the correlation can support of the 
prevention and therapeutic of asthma. Status of 
magnesium was measured by serum magnesium 
14level . Peak Expiratory Flow (PEF) was used to 
15,16measure lung function .
The hypothesis was the serum magnesium 
had the correlation with Peak Expiratory Flow 
(PEF) in chronic asthma patients.
SUBJECTS AND METHODS 
It was a cross-sectional study. Subjects 
were chronic asthma patients who visited to 
Pulmonology Outpatient Department Dr. Sardjito 
General Hospital Yogyakarta, from September 2004 
- March 2005. 
Eligibility criteria for entry in this study 
were as follows: diagnosed as chronic asthma 
patients; more than 18 years old; signs informed 
consent. The exclusion criteria were as follows: 
used diuretic, thiazid, aminoglicoside, siclosporine, 
cisplatin, foscarnet, laxative, oral magnesium, 
enema, antacide, magnesium intravena; alcohol 
abuse; history of diabetes mellitus, heart and renal 
diseases; current diarhhoea; and current pregnancy.
The independent variable is magnesium 
serum. The dependent variable is PEF. The study 
used consecutive sampling. Chronic asthmatics, 
who agreed to take apart in the study were 
interviewed and clinically evaluated. A 
questionnaire that included the patients age, sex, 
duration of asthma, number of hospitalization was 
obtained from each subject.  PEF was measured 3 
times to get the best value. Measurements of serum 
magnesium level were carried out using 
colorimetric from Randox. 
STATISTICAL  ANALYSIS
         The statistical analysis was done using SPSS 
11. Characteristic features were showed by mean 
and standard deviation. Distribution was tested by 
Kolmogorov Smirnov. Correlation between serum 
magnesium levels and PEF were analyzed by 
Pearson correlation test. In all tests, a p value of 
<0.05 was considered significant. The value of 
power was 90%. We used anova to compare mean 
when analyze more than 2 group.
RESULTS
Total 62 chronic asthma patients were 
studied. They were 26 male subjects (41.9%) and   
46 female subjects (58.1%). Mean of ages were 
44.46±11.68 years. Mean of magnesium was 0.89 ± 
0.08 mmol/L. There was no prevalence of 
hypomagnesemia. The study found 1 (2%) subject 
had  hypermagnesaemia  and  61  (98%)  
normomagnesaemia subjects.
 Mean of predictive PEF value was 
61.69±18.16%. Mean duration of asthma was 
10.34±8.88 years.  The study found 6 subjects 
(9.7%) intermittent asthma, 6 subjects (9.7%) mild 
persistent asthma, 15 subjects (24.2%) intermediate 
persistent asthma and 35 subjects (56.5%) severe 
persistent asthma (table 1). Results showed that 
magnesium serum levels and predictive PEF had 
weak correlation (r= 0.281; p=0.027) (table 2). The 
study used scatter plot to show correlation between 
magnesium serum and PEF (graphic 1).
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Table 1. Characteristic features
Variable  Proportion  or mean ± SD
 
 
95% CI Minimum - Maximum
Sex
 
      
Male
 
     
Female
 
Age (years)
 
 
Magnesium (mmol/L)
 
     
hypomagnesemia
 
     
normomagnesemia
 
     
hypermagnesemia
 
PEF predictive (% )
 
Duration of asthma
 
Severity:
intermitten
mild persistent
intermediate persistent 
severe persistent
 26   (41.9%)
 
36  (58.1%).
 
44.46±11.68 
 
0.89 ± 0.08  
 
0
 
61  (98%)
 
1    (2%)
 
61.69±18.16 
 
10.3
 
6   (9.7%)
6   (9.7%)
15 (24.2%)
35 (56.5%)
 
 
 
41.4 – 47.4
0.87 – 0.91
 
 
 
57.0 – 66.3
8.1 – 12.5
18-66 
0.7-1.2
30-101 
1-35
Table 2.  Correlation between Magnesium and PEF
Variabel r p  
Magnesium             0.281
 
                 0.027*  
*significant (<0,05),  Pearson test
Table 3. Correlation between magnesium serum and admission 
to emergency room or hospitalization
Variabel r p  
Number of admission  to ER** 
Number of hospitalizations*** 
0.029*  
0.13*  
0.8  
0.13  
*used  spearman correlation test
** Number of admission to ER on the last one year.
*** Number of hospitalizations on the last one year.
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Graphic 1. Scatter Plot of correlation of predictive PEF (%) and magnesium serum (mmol/L).
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DISCUSSION
This study did not find hypomagnesemia. 
8,17This result was different with previous study . 
This result might be interfered by some factors 
including diet and genetic pattern. The type of diet 
of Yogyakarta population and the method of 
cooking may influence magnesium status. Some 
impairment and variant of genetic pattern could also 
influence magnesium absorption from intestinal and 
18,19,20magnesium excretion through renal . This 
factor could bias of the study. The tight exclusion 
criteria might be excluding the population of 
hypomagnesemia. But the same exclusion criteria 
was used on Alamoudi study in Arab Saudi and 
found prevalence of hypomagnesemia at 
8,17approximately 27% .
The serum magnesium may not reflect a 
true status of magnesium.  Magnesium 
predominantly was in intracellular and only 1% in 
21serum . The correlation between concentration of 
serum magnesium and intracellular magnesium is 
still unclear. Zervas reported that the asthmatic 
acute attack patients had erythrocytes magnesium 
level lower than healthy people or chronic asthma 
patients, but the concentration increased when their 
21condition improved . He reported that erythrocytes 
magnesium level may decrease although the 
21magnesium serum did not change . However, a 
more extended research is needed to support this 
argument. We suggested a larger sample in next 
extended study to achieve a more conclusive result. 
CONCLUSION
The study showed a weak correlation of 
serum magnesium and PEF(r=0.28 p<0.05). This 
result could be influenced by some factors. The 
strong correlation was higher in hypomagnesemia 
population than in normomagnesaemia population. 
This study did not have a hypomagnesaemia 
population so that we cannot analyze this 
probability.
The uncontrolled factor like allergen factor, 
air pollution infection, weather, emotion, food and 
additive might cause bias in this study.
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ABSTRACT
Background: 
. Severe disease can be fatal, 
although majority of cases are mild and self-limited.
Objective: To determine the prognostic 
factors for leptospirosis that associated with 
mortality in patients with leptospirosis in Dr. 
Sardjito General Hospital, Yogyakarta.
e conducted a retrospective 
study of data collected in our hospital between Jan 
2010 until May 2011, from whom the diagnosis of 
leptospirosis was confirmed based on pertinent 
clinical and epidemiological data and positive 
serology.
Result: Thirty two patients were included in 
this study, including 29 survivors (90.62%) and 3 
non-survivors (9.38%). Of these 32 patients, 26 
patients (81.25%) were admitted to the medical 
ward and 6 patients (18.75 %) were admitted to the 
ICU.  Multivariate logistic regression demonstrated 
that three factors were independently associated 
with mortality: higher level of potassium (OR 10.8; 
CI 1.194-97.728; p<0.01) on admission and 
neurological dysfunction (altered mentation or 
seizure) (OR 30; CI 4.367–206.07; p<0.01)
Conclusion: The mortality of leptospirosis 
remains high despite improvements in patients care. 
In order to improve the early treatment of high-risk 
patients, these higher levels of potassium on 
admission and neurological dysfunction, which are 
associated with mortality, can be used at the time of 
admission as prognostic factors.
Leptospirosis, an infectious 
disease that affects humans and animals, is a 
common zoonosis with a variety of clinical 
manifestations. Yogyakarta is one of the cities with a 
high incidence of leptospirosis. It is important to 
recognize the clinical features and prognostic 
factors of this disease
Methods: W
Keywords : Leptospirosis, prognostic factors, 
mortality
Background
Leptospirosis is the most widespread 
zoonosis with recent outbreaks in several Asian, 
1Central, and South American countries.  
Leptospirosis is a zoonotic disease, which is caused 
by Leptospira and transmitted to human by contact 
with Leptospira contaminated animal urine or 
Leptospira contaminated environment. Thirty-two 
patients with Leptospirosis had admitted in Dr. 
Sardjito General Hospital from January 2010 until 
2May 2011.  In Indonesia, the spread of leptospirosis 
is in the Province of West Java, Central Java, 
Yogyakarta, Lampung, South Sumatra, Bengkulu, 
Riau, West Sumatra, North Sumatra, Bali, NTB, 
South Sulawesi, North Sulawesi, East Kalimantan 
and West Kalimantan. The mortality rate of 
leptospirosis in Indonesia is high, reaching 2.5 to 
16.45%. At the age of over 50 years mortality rate 
can be up to 56%. When Leptospirosis patient is 
accompanied by a yellow lining of the eye indicating 
damage to liver tissue, the risk of death will be 
higher. Several publications reported mortality rates 
between 3% -54% depending on the infected organ 
3system.
We believe that early evaluation of disease 
severity at the time of admission might be useful in 
improving the care of patients with leptopsirosis.
Objective
The purpose of this study is to determine the 
prognostic factors for leptospirosis that associated 
with mortality in patients with leptospirosis at Dr. 
Sardjito Hospital, Yogyakarta.
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Table 1. The mean hospital stay ± SD for the survivors
Variabel Survivors Non-survivors p
Gender, n (%)
    
Man
 
Woman
 21
 
8
 3
 
0
 
 
0.55
Age (years ), mean ± 
SD
 42.41
 
± 13.44
 
57.33
 
± 14.43
 
0.2
 
20-46
 
years
 
47-76 years
 17
 
12
 0
 
3
 
 
0.092
At risk occupation, n 
(%) 
   
Yes 
No 
12 
17 
2  
1  
 
0.57
Rodent exposure, n 
(%) 
   
Yes
 No
 
21
 8
 
2
 1
 
 1
 Hemodialisis, n
    Yes
 No
 
10
 19
 
1
 2
 
 1
 ICU, n
    
Yes
No
4
25
2
1 0.083
The mean age ± SD for the survivors was 42.41 years ± 13.44 years, and for the non-survivors was 57.33 years 
± 14.43 years. In age variable there was no differences between the survivors and non survivors (p = 0.092)
The gender ratio between male and female patients with leptospirosis was  3:1, man 75% and women 
25%. There was no differences in gender between the survivors and non survivors (p = 0.55)
Table 2. Clinical sign and symptoms in survivors and non survivors among patients with Leptospirosis
Sign and 
symptoms
 Survivors
 
(n =
 
29
 
)
 
Non survivors
 
(n =
 
3
 
)
 
p
 
value
 
Fever
 
2
  
0
 
1.000
 
Dyspnea
 
15
 
2
 
1.000
 
Jaundice 19 3  0.534  
Cardiovascular 
collapse 
16 1  0.589  
Conjunctival 
Suffusion 
21 2  1.000  
Oliguria 9 3  0.044*  
Respiratory 
symptoms
 
7 2  0.184  
Neurological 
dysfunction
 
0
 
2
 
0.006*
 
Hemorragic 1 1 0.181
*statistically significant
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Table 3. Result of univariate analysis of laboratory values between survivors and non-survivors among 
patients with leptospirosis.
Value Survivors (n = 29) Nonsurvivors (n = 3)  p
Urea nitrogen  
(mg/dL)
 79.12 ± 43.14 139 ±  6.56  0.000*  
Creatinine (mg/dL)
 
6.17 ±
 
3.32
 
8.43 ±
 
3.75
 
0.275
 
Total protein (g/L)
 
5. 71 ±
 
0.69
 
5.6 ±
 
0.21
 
0.793
 
Albumin (g/L)
 
2.11 ±
 
0.46
 
1.61 ±
 
0.27
 
0.081
 
Total Bilirubun 
(mmol/L) 
7.76 ± 8.59
 
14.48 ± 4.78
 
0.099
 
Sodium (mmol/L) 125.9 ± 9.67 144.2 ±  15.77  0.027  
Potassium (mmol/L) 4.05 ± 0.81 5.29 ±  1.08  0.02*  
Chloride (mmol/L) 93.98 ± 10.23 100 ±  15.62  0.359  
Uric (mg/dL) 9.46 ± 3.66 11.5 ±  2.95  0.286  
AST (IU/L) 71 ± 46.2 123 ±  110.59  0.365  
ALT (IU/L) 53.58 ± 24.38 84.67 ±  48.44  0.064  
Glucose (mg/dL)
 
132.17 ±
 
72.02
 
115 ±
 
33.41
 
0.628
 WBC count  (109/L)
 
14.39 ±
 
5.29
 
13.74 ±
 
2.53
 
0.837
 Platelet 
 
count  
(109/L)
 
115.41 ±
 
87.05
 
76.67 ±
 
84.51
 
0.301
 
Hemoglobin (g/L)
 
11.84 ±
 
1.54
 
11.5 ±
 
0.26
 
0.305
 Hematocrit (%) 33.19 ± 4.59 32.5 ± 1.9 0.651
*statistically significant
Table 4. Result of multivariate stepwise logistic regression analysis of risk factors for patients with 
Leptospirosis.
Risk Factor
 
OR
 
95% CI
 
P value
 
Oliguria 0.75 0.541 –  1.04  0.018  
Urea nitrogen  
(mg/dL) 
0.813 0.642 -  1.028  0.025  
Potassium 
(mmol/L) 
10.8 1.194  –  97.728  0.009  
Neurological 
symptoms
 
30 4.367 –  206.07  0.000  
Discussion
In this study, several poor prognostic 
factors in leptospirosis have been identified, 
including higher admission serum potassium and 
neurological dysfunction (altered mentation or 
seizures) were associated with high in-hospital 
8fatality.  In another retrospective study, advanced 
age, oliguria, cardiac arrhythmia, dyspnea, and 
9pulmonary rales were associated with mortality.
Mortality in leptospirosis ranges from 1% 
1, 10, 11to 20 %.  In South India, a mortality of 5.32% 
was reported from Kolenchery and 3.5% from 
Madras. The study showed that there was no 
difference in mortality when patients were grouped 
by age, gender, at-risk occupation, or rodent 
exposure.
ARF occurs in 16% to 40% of leptospirosis 
and approximately 30% to 50% are non-oliguric, 
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10with a worse prognosis for oliguric renal failure.  
Ninety-seven percent of the patients had renal 
failure and all patients who died were oliguric. In 
our study, oliguria was a very sensitive criterion of 
the severity of the disease. Similarly, Seguro et al 
noted that the mortality rate for oliguric patients 
with acute renal failure were higher than that for 
patients with persistent dieresis. Again, 90% of 
leptospirosis is anicteric with a lower mortality 
compared with icteric forms. In our group, 68% of 
patients were icteric and there was no difference in 
mortality. 
Neurologic dysfunction (altered mentation 
or seizures) was the most significant predictor of 
mortality; most patients with neurologic 
dysfunction also had significant renal and hepatic 
disease contributing to encephalopathy. Altered 
mental status was the strongest independent 
predictor of death in urban leptospirosis in Brazil; 
other poor prognostic factors were oliguria, 
advanced age, renal and respiratory insufficiency. In 
this study, there was an association between altered 
12mental status and mortality.
Conclusions
The mortality of leptospirosis remains high 
despite improvements in patients care. In order to 
improve the early treatment of high-risk patients, 
these two clinically and two laboratory criteria, 
independently associated with mortality, could be 
used at the time of admission.
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